Results 91 to 100 of about 29,513 (309)

HCV treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. [PDF]

, 2013
UNLABELLED: Substantial reductions in hepatitis C virus (HCV) prevalence among people who inject drugs (PWID) cannot be achieved by harm reduction interventions such as needle exchange and opiate substitution therapy (OST) alone. Current HCV treatment is
Aitken, Allen, Berg, Burns, Cohen, Cohen, Cornish, Dahari, Dimova, Dore, Gane, Grebely, Grebely, Hagan, Hallinan, Harris, Health Protection Scotland and the University of the West of Scotland, Hellard, Hellard, Hickman, Innes, Iverson, Iverson, Jacobson, Kemp, Kim, Kimber, Kirwan, Lindenburg, Lindenburg, Liu, Liu, Ly, Maher, Martin, Martin, Martin, Mathers, McCaw, McInnes, Mehta, Micallef, Mondelli, Nelson, Nosyk, O'Keefe, Poordad, Poordad, Quinn, Shepard, Stoove, Sweeting, Turner, Vickerman, Vickerman, Wood, Zeiler   +56 more
core   +5 more sources

Biomimetic Copper Nanoparticles Coated with ACE2‐Overexpressing Membranes for Selective SARS‐CoV‐2 Neutralization and Disinfection

Advanced Healthcare Materials, EarlyView.
By fusing ACE2‐overexpressing membrane‐integrated liposome (MIL) with copper nanoparticles, the biomimetic Cu@MIL nanostructures were created that directly hijack the SARS‐CoV‐2 entry pathway. These particles combine potent virus‐targeting precision with intrinsic antiviral activity, achieving rapid neutralization and disinfection.
Pooja Aich, Wei‐Pang Chung, Wen‐Jyun Wang, Hidenobu Takahashi, Ming‐Shun Hsieh, Ying‐Chen Lin, Oh Seok Kwon, Wei‐Peng Li, Wei‐Lun Huang   +8 more
wiley   +1 more source

Hepatitis C Treatment: A Review and Update

Southeastern European Medical Journal, 2017
Hepatitis C virus infection (HCV) infects approximately 185 million individuals worldwide. It is a leading cause of chronic liver disease and the primary reason for liver transplantation.
Jelena Jakab, Marinko Žulj, Nikola Volarić, Bojan Tepeš, Aleksandar Včev   +4 more
doaj   +1 more source

Metabolic syndrome does not affect sustained virologic response of direct-acting antivirals while hepatitis C clearance improves hemoglobin A1c. [PDF]

, 2018
AimTo determine whether successful treatment with directacting antivirals (DAA) is associated with improvements in hemoglobin A1c (HbA1c) and if type 2 diabetes mellitus (T2DM) or metabolic syndrome affects sustained virologic response (SVR).MethodsWe ...
Aby, Elizabeth S, Benhammou, Jihane N, Dong, Tien S, Han, Steven-Huy, Kawamoto, Jenna, May, Folasade P, Pisegna, Joseph R   +6 more
core  

Hepatitis C virus infection and related liver disease: the quest for the best animal model [PDF]

, 2013
Hepatitis C virus (HCV) is a major cause of cirrhosis and hepatocellular carcinoma (HCC) making the virus the most common cause of liver failure and transplantation.
Baumert, Thomas F, Mailly, Laurent, Meuleman, Philip, Robinet, Eric, Zeisel, Mirjam   +4 more
core   +3 more sources

Opinion: Gavage Administration of MXene as a Route‐Specific Alternative to Intravenous Injection into the Bloodstream of Laboratory Animals for Reducing Systemic Nanotoxicity Risks in Immunosuppression and Post‐Transplantation Models with Bile Acid Modification

Advanced Healthcare Materials, EarlyView.
Recent studies reported immunosuppressive properties of specific MXene nanomaterials. Their intravenous injection into the bloodstream of laboratory animals has been a common delivery method to suppress systemic inflammation and prevent transplant rejection.
Alireza Rafieerad, M. Akif Rahman, Ahmad Amiri   +2 more
wiley   +1 more source

Profile of alisporivir and its potential in the treatment of hepatitis C

Drug Design, Development and Therapy, 2013
Philippe A Gallay,1 Kai Lin21Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, 2Permeon Biologics Inc, One Kendall Square, Cambridge, MA, USAAbstract: Two classes of hepatitis C antiviral agents currently exist,
Gallay PA, Lin K
doaj  

Access to direct-acting antivirals for the treatment of hepatitis C in a country with limited resources

Revista de Gastroenterología de México (English Edition), 2018
Aims: To estimate the number of patients that have access to treatment of hepatitis C with direct-acting antivirals in Argentina and evaluate the factors associated with the lack of access.
S. Marciano, L. Haddad, S.M. Borzi, C. D’Amico, L.A. Gaite, M.V. Aubone, M.E. Sirotinsky, N. Ratusnu, M.S. Frola, M.C. Aparicio, B. Ríos, M.N. Anselmo, R. Hansen, S. De Filippi, C. García Dans, L. de Labra, M.A. Peche, T.M. Strella, M. Ibáñez Duran, M.B. García Rosales, M. Dirchwolf, O.A. Galdame, A.C. Gadano   +22 more
doaj   +1 more source

Curing Hepatitis C in Liver Transplant Recipients Is Associated with Changes in Immunosuppressant Use. [PDF]

, 2016
Background and aimsAll-oral interferon-free antivirals are highly effective in treating recurrent hepatitis C (HCV) infection in liver transplant (LT) recipients.
Bau, Sherona, Busuttil, Ronald W, Choi, Gina, Durazo, Francisco, El Kabany, Mohammed, Elashoff, David, Farid, Alexander, Grotts, Jonathan, Han, Steven, Jamal, Naadir, Jimenez, Melissa, Rheem, Justin, Saab, Sammy   +12 more
core   +2 more sources

Dynamic modelling of hepatitis C virus transmission among people who inject drugs: a methodological review [PDF]

, 2014
Equipment sharing among people who inject drugs (PWID) is a key risk factor in infection by hepatitis C virus (HCV). Both the effectiveness and cost-effectiveness of interventions aimed at reducing HCV transmission in this population (such as opioid ...
Cousien, Anthony, Deuffic-Burban, Sylvie, Dhersin, Jean-Stephane, Jauffret-Roustide, Marie, Tran, Viet Chi, Yazdanpanah, Yazdan   +5 more
core   +5 more sources